【摘要】：在諸多評(píng)估雌激素受體(estrogen receptor,ER)陽(yáng)性早期乳腺癌復(fù)發(fā)風(fēng)險(xiǎn)的多基因工具中,Oncotype DX 21基因檢測(cè)因其獨(dú)特的療效預(yù)測(cè)作用而被廣泛應(yīng)用于淋巴結(jié)陰性患者。多項(xiàng)回顧性研究已證明其在淋巴結(jié)陽(yáng)性人群同樣具有預(yù)后預(yù)測(cè)價(jià)值,但前瞻性臨床試驗(yàn)證據(jù)仍不充分。該檢測(cè)能協(xié)同其他重要臨床病理因素,影響乳腺癌患者的輔助治療方案,且具較高的成本效益。該研究就21基因檢測(cè)對(duì)早期乳腺癌患者的預(yù)后預(yù)測(cè)價(jià)值、獨(dú)特優(yōu)勢(shì)、輔助治療決策影響、成本效果和現(xiàn)存爭(zhēng)議進(jìn)行綜述。
[Abstract]:The detection of, Oncotype DX 21 gene has been widely used in lymph node negative patients due to its unique predictive effect of estrogen receptor (estrogen receptor,ER) positive early breast cancer recurrence risk. A number of retrospective studies have shown that it also has prognostic value in lymphaden-positive populations, but the evidence in prospective clinical trials is still insufficient. It can be combined with other important clinicopathological factors to influence the adjuvant treatment of breast cancer patients and is cost-effective. This study reviewed the prognostic value, unique advantages, effect of adjuvant therapy decision, cost effectiveness and current controversy of 21 gene detection in patients with early breast cancer.
【作者單位】： 復(fù)旦大學(xué)附屬腫瘤醫(yī)院乳腺外科復(fù)旦大學(xué)上海醫(yī)學(xué)院腫瘤學(xué)系;
【分類號(hào)】：R737.9
，

本文編號(hào)：2281072